FP7 logo euThe SATURN project has received funding from the European Community's Seventh Framework Programme [FP7/2007-2013] under grant agreement n°241796

Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria

Partners: Radboud University Nijmegen Medical Center – (RUNMC)

The organisation

Radboud University Nijmegen is one of the leading academic communities in the Netherlands. Established in 1923 and situated in the oldest city of The Netherlands, it has nine faculties and enrols over 17.500 students. The medical faculty is an important part of the University and, together with the hospital, forms the Radboud University Nijmegen Medical Centre. Research on infectious diseases in all its aspects is one of the key research areas and is centred in the N4i institute. The institute participates in many large projects, including FP7 projects. The department of medical microbiology and infectious diseases has several major research areas, including Malaria. Clinical mycology is also an important focus, including pharmacodynamics of antimycotic agents and molecular epidemiology. Emergence of resistance is one of the key elements – recently the group described emergence of azole resistance in A. fumigatus for the first time.  The department and N4i institute have vast experience in hospital epidemiology and rational use of antibiotics.

Key staff involved in the project

Johan W Mouton, MD, PhD: was trained as a medical scientist as well as medical microbiologist and is currently consultant of the department of microbiology and infectious diseases. Research is focused on two main areas, epidemiology of resistance and antimicrobial pharmacodynamics. He is well known for his work on exposure response relationships, and optimising antimicrobial therapy both in terms of efficacy as well as emergence of resistance. He has authored several collaborative papers to further standardise approaches in the field. He served as the president of the International Society of Antiinfective Pharmacology, is member of the steering committee of the EUCAST (European Committee on Antimicrobial Susceptibility Testing), among other offices. He has published >150 papers in peer-reviewed scientific journals.

Andreas Voss MD, PhD: is coordinator of the regional infection control group. He is also Professor of Clinical Microbiology and Infection Control Hospital Epidemiology at the Radboud University Nijmegen (UMCN). He received his MD at the Technical University in Munich, Germany. He was a fellow-associate at the University of Iowa Clinics and Hospitals and later finished his training as a medical microbiologist at the UMCN, where he also received his PhD. Current positions include director of ECCMID and member of the WHO core group on hand hygiene. His research is focused on hospital epidemiology. In European projects, he is currently involved in IPSE and is a WP leader in PILGRIM. He has published >120 papers in peer-reviewed scientific journals.

Inge Gyssens, MD, PhD: was trained as an infectious disease specialist and has worked at University, Radboud University Nijmegen, Erasmus University Rotterdam. She has a professorship in Hasselt, Belgium and a research appointment at the RUNMC. Her main research interests include pharmacodynamics and antimicrobial policy, in particular rational use of antibiotics. She is a prominent member of ESGAP and the Dutch Working Party on Antimicrobial Policies and has several collaborations in the developing world on that issue. She has published >80 papers in peer-reviewed scientific journals.

Top ^